Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × OTHER × Fruquintinib × Clear all

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1291 Neoplasms 1014 Prostatic Neoplasms 681 Lung Neoplasms 557 Colorectal Neoplasms 538 Carcinoma, Non-Small-Cell Lung 500 Carcinoma, Hepatocellular 380 Pancreatic Neoplasms 371 Leukemia, Myeloid, Acute 342 Stomach Neoplasms 317 Multiple Myeloma 286 Ovarian Neoplasms 275 Brain Neoplasms 274 Head and Neck Neoplasms 258 Neoplasm Metastasis 240 Precursor Cell Lymphoblastic Leukemia-Lymphoma 237 Rectal Neoplasms 235 Esophageal Neoplasms 228 Uterine Cervical Neoplasms 223 Melanoma 221 Recurrence 209 Glioblastoma 203 Lymphoma 196 Squamous Cell Carcinoma of Head and Neck 195 Sarcoma 190 Urinary Bladder Neoplasms 179 Colonic Neoplasms 178 Glioma 174 Triple Negative Breast Neoplasms 163 Hematologic Neoplasms 162

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡